{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-003766","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2026-05-13T12:05:18+00:00","discovered_at":"2026-05-13T12:10:00.353567+00:00","generated_at":"2026-05-13T12:17:39.315513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xenetic Biosciences Q1 2026 net loss down 49% to $0.5M; royalty revenue up 36% to $0.8M","bullets":["Net loss of $0.5M ($0.04 per share) vs $0.9M a year ago; cash $7.3M at March 31, 2026.","Royalty revenue $0.8M (+36% YoY) primarily from Takeda sublicense agreement.","R&D expenses $0.7M (-25% YoY) due to lower preclinical costs; G&A $0.6M, flat.","DNase I platform progress: translational data, manufacturing readiness, Israeli Ministry of Health approval for CAR T study.","Company continuing evaluation of strategic alternatives to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003766","json":"https://secwatch.observer/filing/0001683168-26-003766.json","markdown":"https://secwatch.observer/filing/0001683168-26-003766.md","text":"https://secwatch.observer/filing/0001683168-26-003766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/0001683168-26-003766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:17:39.315513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6251ad95373497a71ec7a6dbe9b0a71cefb0ef37","claim":"Xenetic Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue approximately $0.8 million, net income approximately $0.5 million.","evidence_excerpt":"Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826003766/0001683168-26-003766-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"approximately $0.8 million"},{"label":"Net income","value":"approximately $0.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}